CUE – Cue Biopharma Inc
Cue Biopharma, Inc.CUE
$1.31Name : Cue Biopharma, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $82,988,888.00
EPSttm : -0.91
Cue Biopharma, Inc.
$1.31
2.34%$0.03Float Short %
2.07
Margin Of Safety %
Put/Call OI Ratio
0.24
EPS Next Q Diff
0.02
EPS Last/This Y
0.36
EPS This/Next Y
0.19
Price
1.32
Target Price
3.6
Analyst Recom
1
Performance Q
22.43
Relative Volume
0.35
Beta
1.63
Ticker: CUE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | CUE | 1.03 | 0.07 | 5.00 | 2293 |
| 2024-12-20 | CUE | 1.03 | 0.07 | 0.00 | 2293 |
| 2024-12-23 | CUE | 1.04 | 0.09 | 999.99 | 1653 |
| 2024-12-24 | CUE | 1.01 | 0.09 | 999.99 | 1653 |
| 2024-12-26 | CUE | 1.07 | 0.10 | 0.04 | 1660 |
| 2024-12-27 | CUE | 1.06 | 0.10 | 0.04 | 1660 |
| 2024-12-30 | CUE | 1.02 | 0.10 | 0.00 | 1666 |
| 2024-12-31 | CUE | 1.08 | 0.10 | 0.80 | 1672 |
| 2025-01-02 | CUE | 1.07 | 0.11 | 0.00 | 1698 |
| 2025-01-03 | CUE | 1.39 | 0.11 | 0.00 | 1699 |
| 2025-01-06 | CUE | 1.74 | 0.10 | 0.00 | 1777 |
| 2025-01-07 | CUE | 1.6 | 0.09 | 0.43 | 1980 |
| 2025-01-08 | CUE | 1.44 | 0.10 | 0.06 | 1968 |
| 2025-01-09 | CUE | 1.45 | 0.10 | 0.06 | 1968 |
| 2025-01-10 | CUE | 1.51 | 0.10 | 6.14 | 1970 |
| 2025-01-13 | CUE | 1.34 | 0.12 | 0.73 | 2018 |
| 2025-01-14 | CUE | 1.21 | 0.12 | 0.50 | 1980 |
| 2025-01-15 | CUE | 1.3 | 0.12 | 0.00 | 1975 |
| 2025-01-16 | CUE | 1.26 | 0.12 | 17.67 | 1981 |
| 2025-01-17 | CUE | 1.32 | 0.24 | 0.00 | 2156 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | CUE | 1.02 | 50.0 | - | -0.76 |
| 2024-12-20 | CUE | 1.03 | 50.0 | - | -0.76 |
| 2024-12-23 | CUE | 1.04 | 50.0 | - | -0.76 |
| 2024-12-24 | CUE | 1.01 | 50.0 | - | -0.76 |
| 2024-12-26 | CUE | 1.08 | 50.0 | - | -0.76 |
| 2024-12-27 | CUE | 1.05 | 50.0 | - | -0.76 |
| 2024-12-30 | CUE | 1.02 | 50.0 | - | -0.76 |
| 2024-12-31 | CUE | 1.08 | 50.0 | - | -0.76 |
| 2025-01-02 | CUE | 1.08 | 50.0 | - | -0.76 |
| 2025-01-03 | CUE | 1.40 | 50.0 | - | -0.76 |
| 2025-01-06 | CUE | 1.74 | 50.0 | - | -0.76 |
| 2025-01-07 | CUE | 1.59 | 50.0 | - | -0.76 |
| 2025-01-08 | CUE | 1.45 | 50.0 | - | -0.76 |
| 2025-01-09 | CUE | 1.45 | 50.0 | - | -0.76 |
| 2025-01-10 | CUE | 1.50 | 50.0 | - | -0.76 |
| 2025-01-13 | CUE | 1.34 | 50.0 | - | -0.76 |
| 2025-01-14 | CUE | 1.21 | 50.0 | - | -0.76 |
| 2025-01-15 | CUE | 1.30 | 50.0 | - | -0.76 |
| 2025-01-16 | CUE | 1.27 | 50.0 | - | -0.76 |
| 2025-01-17 | CUE | 1.32 | 50.0 | - | -0.76 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | CUE | 7.15 | 0.42 | 1.60 |
| 2024-12-20 | CUE | 7.15 | 0.42 | 1.60 |
| 2024-12-23 | CUE | 7.22 | 0.42 | 1.60 |
| 2024-12-24 | CUE | 6.81 | 0.42 | 1.60 |
| 2024-12-26 | CUE | 6.95 | 0.42 | 1.71 |
| 2024-12-27 | CUE | 6.60 | 0.42 | 1.71 |
| 2024-12-30 | CUE | 7.02 | 0.36 | 1.71 |
| 2024-12-31 | CUE | 7.02 | 0.36 | 1.71 |
| 2025-01-02 | CUE | 6.28 | 0.36 | 1.71 |
| 2025-01-03 | CUE | 6.74 | 0.36 | 1.71 |
| 2025-01-06 | CUE | 5.21 | 0.36 | 1.71 |
| 2025-01-07 | CUE | 5.21 | 0.36 | 1.71 |
| 2025-01-08 | CUE | 6.74 | 0.36 | 1.71 |
| 2025-01-09 | CUE | 6.74 | 0.36 | 1.71 |
| 2025-01-10 | CUE | 6.74 | 0.36 | 1.71 |
| 2025-01-13 | CUE | 6.74 | 0.36 | 2.07 |
| 2025-01-14 | CUE | 6.74 | 0.36 | 2.07 |
| 2025-01-15 | CUE | 6.74 | 0.36 | 2.07 |
| 2025-01-16 | CUE | 6.74 | 0.36 | 2.07 |
| 2025-01-17 | CUE | 6.74 | 0.36 | 2.07 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.17
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
-0.15
Insider Transactions
6.74
Institutional Transactions
0.36
Beta
1.63
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
20
Growth Score
45
Sentiment Score
6
Actual DrawDown %
95.8
Max Drawdown 5-Year %
-98.5
Target Price
3.6
P/E
Forward P/E
PEG
P/S
8.71
P/B
3.11
P/Free Cash Flow
EPS
-0.91
Average EPS Est. Cur. Y
-0.76
EPS Next Y. (Est.)
-0.57
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-468.02
Relative Volume
0.35
Return on Equity vs Sector %
-195
Return on Equity vs Industry %
-182.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.06
EBIT Estimation
Cue Biopharma, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 53
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
stock quote shares CUE – Cue Biopharma Inc Stock Price stock today
news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CUE – Cue Biopharma Inc yahoo finance google finance
stock history CUE – Cue Biopharma Inc invest stock market
stock prices CUE premarket after hours
ticker CUE fair value insiders trading